Adjuvants: Classification, Modus Operandi, and Licensing

Autor(es)

Apostolico, Juliana de Souza ; Santos Lunardelli, Victoria Alves ; Coirada, Fernanda Caroline ; Boscardin, Silvia Beatriz ; Rosa, Daniela Santoro

• Tipo de documento: Artigo Científico
• Fonte: JOURNAL OF IMMUNOLOGY RESEARCH; v. 2016, p. 16-pg., 2016-01-01.

Resumo

Vaccination is one of the most efficient strategies for the prevention of infectious diseases. Although safer, subunit vaccines are poorly immunogenic and for this reason the use of adjuvants is strongly recommended. Since their discovery in the beginning of the 20th century, adjuvants have been used to improve immune responses that ultimately lead to protection against disease. The choice of the adjuvant is of utmost importance as it can stimulate protective immunity. Their mechanisms of action have now been revealed. Our increasing understanding of the immune system, and of correlates of protection, is helping in the development of new vaccine formulations for global infections. Nevertheless, few adjuvants are licensed for human vaccines and several formulations are now being evaluated in clinical trials. In this review, we briefly describe the most well known adjuvants used in experimental and clinical settings based on their main mechanisms of action and also highlight the requirements for licensing new vaccine formulations. (AU)

• Processo FAPESP: 13/11442-4 - Estudo dos mecanismos protetores induzidos pela vacinação de camundongos com anticorpos de fusão capazes de direcionar proteínas do vírus da dengue para células dendríticas
• Beneficiário: Silvia Beatriz Boscardin
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 14/15061-8 - Direcionamento in vivo de epitopos de linfócitos TCD4+ do HIV-1 para células dendríticas
• Beneficiário: Daniela Santoro Rosa
• Modalidade de apoio: Auxílio à Pesquisa - Regular